ELFBAR's LOSTMARY nicotine levels exceeded legal limit

Mar.05.2023
ELFBAR's LOSTMARY nicotine levels exceeded legal limit
ELFBAR's LOSTMARY e-cigarette products exceeded UK legal limits for nicotine content by over 50%.

According to reports from the Daily Mail and Mirror, on the evening of March 4th, ELFBAR's product LOSTMARY was found to contain over 50% more nicotine than the legal limit in the UK. This marks the second time this year that ELFBAR has exceeded the allowable nicotine levels in the UK.


According to a report, further testing on five BM600 dual apple-flavoured electronic cigarettes purchased from Sainsbury's supermarket revealed that they contain an average of 3.6ml of e-liquid. Meanwhile, five identical watermelon ice-flavoured e-cigarettes purchased from Asda were found to contain an average of 3.2ml of e-liquid.


According to a test conducted by the Daily Mail, some BM600 products contain nicotine levels exceeding the maximum permissible limit of 80%. The Daily Mail further explains that the reason for the exceeding nicotine levels is due to the e-cigarette liquid containing 3.6ml (the legal limit being 2ml). However, the Daily Mail did not indicate whether the nicotine concentration exceeded the legal standard of 2%.


UK supermarket chains Sainsbury's and Asda have announced that they will be removing the LOST MARY BM600 product from their shelves after receiving test results.


According to reports, electronic cigarette manufacturers are required to register detailed information about their products (such as nicotine content) with the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be sold in the UK. However, the MHRA does not conduct any testing on electronic cigarettes during the product registration process.


The MHRA will only take action upon receiving a product violation alert, such as exceeding regulatory limits on nicotine content.


Professor Andrew Bush, a pediatric specialist from Imperial College London, expressed shock and concern over the findings, stating, "This is absolutely shocking. If the media is needed to expose such significant misconduct, then what is the role of our regulatory systems?" in an interview with The Daily Mail.


Andrew Bush stated, "There is an urgent need for compliance checks to be conducted when manufacturers register e-cigarettes, with further spot checks conducted after e-cigarettes are released to ensure companies are following the law.


Chris Allen, CEO of the Brouton Laboratory conducting the tests, has called for regulatory authorities to swiftly address the issue. He has urged them to take strong actions such as removing the products that exceed the limits, conducting product testing, and disposing of non-compliant products.


The Daily Mail reported that they reached out to ELFBAR for comments on LOST MARY product testing but did not receive a response.


2FIRSTS will continue to monitor the situation and conduct interviews with ELFBAR, MHRA, and other related organizations. Stay tuned for updates.


Related Reading: "ELFBAR 600 Product Removal" Special Topic Summary


Reference:


Supermarkets have removed a specific type of vape device from their stores following discovery that it contained at least 50% more nicotine than is legal.


Two major supermarkets have removed another vaping product from their shelves due to concerns about its safety.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06